<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94060">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01867255</url>
  </required_header>
  <id_info>
    <org_study_id>12-005860</org_study_id>
    <nct_id>NCT01867255</nct_id>
  </id_info>
  <brief_title>Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels</brief_title>
  <official_title>Pharmacokinetic Study Comparing Area Under the Curve for a Single Dose of Venlafaxine ER Pre- and Post-gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether a significant and predictable change in
      bioavailability of extended-release venlafaxine occurs following Roux-en-Y gastric bypass.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Venlafaxine levels pre- and post-gastric bypass</measure>
    <time_frame>3 to 4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>This study will measure and compare venlafaxine and desvenlafaxine levels in participants before, and again 3 to 4 months after, gastric bypass surgery.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Bariatric Surgery</condition>
  <condition>Gastric Bypass</condition>
  <condition>Roux-en-Y Gastric Bypass</condition>
  <arm_group>
    <arm_group_label>venlafaxine ER</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>venlafaxine ER (extended-release) 75 mg once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine ER (extended-release) 75 mg</intervention_name>
    <description>A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.</description>
    <arm_group_label>venlafaxine ER</arm_group_label>
    <other_name>Effexor XR 75 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Approved to undergo Roux-en-Y gastric bypass surgery (cost of surgery is NOT included in
        the study)

        Exclusion criteria:

          -  Pregnant

          -  Allergy to venlafaxine or desvenlafaxine

          -  Psychiatric hospitalization within the prior 12 months

          -  Active professional treatment for recent substance abuse within 12 months of
             abstinence

          -  Ongoing psychologic issues, such as personality disorders, difficulties as a trauma
             survivor, or difficulties with depression unless a stable, documented course of
             treatment by a licensed mental health professional is available

          -  Current use of any of the following medications/supplements:  5-hydroxytryptophan,
             almotriptan, amitriptyline, amoxapine, amoxicillin-clavulanate,
             amphetamine-dextroamphetamine, atazanavir, bupropion, cinacalcet, citalopram,
             clarithromycin, clomipramine, desipramine, desvenlafaxine, dextroamphetamine,
             dextromethorphan, doxepin, duloxetine, eletriptan, entacapone, escitalopram,
             fluoxetine, fluvoxamine, frovatriptan, haloperidol, imipramine, isocarboxazid,
             itraconazole, jujube seed extract, linezolid, maprotiline, methylene blue,
             metoclopramide, metoprolol, milnacipran, mirtazapine, naratriptan, nefazodone,
             nelfinavir, nortriptyline, paroxetine, phenelzine, procarbazine, protriptyline,
             quinidine, rasagiline, ritonavir, rizatriptan, saquinavir, selegiline, sertraline,
             St. John's wort, sumatriptan, tapentadol, terbinafine, toremifene, tramadol,
             tranylcypromine, trazodone, trifluoperazine, trimipramine, tryptophan, L-tryptophan,
             venlafaxine, vilazodone, zolmitriptan
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carrie Krieger, PharmD, RPh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carrie A Krieger, PharmD</last_name>
    <phone>507-266-5311</phone>
    <email>krieger.carrie@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie L Cunningham, PharmD</last_name>
    <phone>507-255-5866</phone>
    <email>cunningham.julie2@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie A Krieger, PharmD</last_name>
      <phone>507-266-5311</phone>
      <email>krieger.carrie@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie A Krieger, PharmD</last_name>
      <phone>507-255-5866</phone>
      <email>cunningham.julie2@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Julie L Cunningham, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin J Somers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael G Sarr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd A Kellogg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Grothe, PhD, LP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn M Schak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyle R Cedermark, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel M Reid, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew M Clark, PhD, LP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria L Collazo-Clavell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Carrie A. Krieger</investigator_full_name>
    <investigator_title>PharmD, BCACP</investigator_title>
  </responsible_party>
  <keyword>venlafaxine</keyword>
  <keyword>Effexor</keyword>
  <keyword>antidepressive agent</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Venlafaxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
